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progression of hepatocellular tumor 
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domain receptor 1
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C1q is known to perform several functions in addition to the role it plays in complement activation. 
C1q contains a collagen-like portion and DDR1 (discoidin domain receptor 1) is a well-known collagen 
receptor. Accordingly, we hypothesized C1q might be a novel ligand of DDR1. This study shows for the 
first time C1q directly induces the activation and upregulation of DDR1, and that this leads to enhanced 
migration and invasion of HepG2 cells. In addition, C1q was found to induce the activations of mitogen-
activated protein kinases (MAPKs) and phosphoinositide 3-kinase (PI3K)/Akt signaling, and to increase 
the expressions of matrix metalloproteinases (MMP2 and 9). Our results reveal a relationship between 
C1q and DDR1 and suggest C1q-induced DDR1 activation signaling may be involved in the progression 
of hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) is one of the most aggressive liver tumors and accounts for ~5% of all malig-
nant neoplasms. To date, no effective treatment strategy is available for HCC, and this would appear to be largely 
due to insufficient understanding of the etiologic and pathogenic mechanisms involved1–3. Therefore, it has been 
suggested improved understanding of the molecular targets underlying the development, metastasis, and inva-
siveness of hepatic cancer cells would certainly aid the developments of better treatments4. Many reports have 
described C1q biosynthesis in several different cells, such as, epithelial cells, fibroblasts, monocytes, dendritic 
cells, Kupffer cells, and microglial cells5,6. C1q plays an important role during tumor development, and a recent 
study reported that C1q contributes to C-activation and independent tumor growth, and that C1q can promote 
cancer cell adhesion, migration and proliferation7. Patients with HCC, acute hepatitis, chronic aggressive hepati-
tis, and patients with cirrhosis have elevated serum C1q levels, and it has been reported serum C1q levels increase 
with the progress of liver damage8,9.
C1 is the first component of the classical pathway of the complement (C) system and is composed of a complex 
of three proteins, that is, C1q, C1r and C1s. In serum, 70% of C1 is present as C1 complex and 30% is dissociated 
as C1q and C1r-C1s. C1q consists of three types of polypeptides chains (A, B, and C chains), each of which con-
tain a C-terminal globular head region (gC1q) and a N-terminal collagen-like Gly/Pro-rich central repeat region 
(CLR)10. Normally, C1q binding to IgG molecules results in the classical pathway of complement activation11. 
However, C1q has many functions such as cell differentiation, migration, invasion, survival and adhesion, as well 
as its role as a complement that can be mediated by cell surface receptors12,13. To date, the receptors for C1q are 
known to the C1q spherical head region receptor such as gC1qR (p33 or C1qBP) and the collagen-like repeat 
region receptor such as calreticulin (CRT or cC1qR), CD93 (C1qRp), CR1, alpha2 beta 1 integrin, CD91 and 
LAIR-112,14. Although several different cell types bind to and respond to C1q, the signaling mechanisms involved 
in the initiation of cellular response to C1q are not well understood11.
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Disordin domain receptors (DDR) -1 and 2 are collagen receptors and members of a new class of receptor 
tyrosine kinases (RTKs) characterized by a 155-amino acid discordin homology domain in their extracellular 
regions. DDR consists of two types of non-integrin collagen receptors, DDR1 and DDR2, and is activated by 
receptor-specific collagen binding15. DDRs are activated by binding to collagen. DDR1 is activated by various 
types of collagen, including types I, II, III, IV, V, VI and VIII, whereas DDR2 is activated only by type I, II and III 
fibrillar collagens and non-fibrillar type X collagen16–20. However, DDRs are not activated by individual chains, 
denatured collagen, deglycosylated or degraded collagen21,22. The activations of collagen-mediated DDRs are 
characterized by slow, sustained activity23,24, and the up-regulation of DDR1 expression has been detected in 
several cancer types, including brain, esophageal, ovarian, and breast cancer25,26. Moreover, sustained DDR1 acti-
vation is known to regulate MMPs, which are well-known to be associated with the invasion and migration of 
cancer cells due to their abilities to degrade ECM components27. Previously, we reported that DDR1 overexpres-
sion enhances the migration and invasion of HCC cells via MMP production and thereby ECM degradation26. 
DDR1 is a well-known collagen receptor, but a report on collagen-independent signaling raised the exciting 
possibility that DDR1 has other as yet unidentified ligands28.
C1q has been reported to exhibit sequence and structural similarities with collagen VIII and X29,30 and it has 
been shown the collagen receptors α2β1 and LAIR-1, are also receptors for C1q collagen-like repeat regions14,31. 
So, we hypothesized that C1q might be a ligand of DDR1 (a known collagen receptor), and undertook this study, 
to investigate the molecular mechanisms of C1q and DDR1 in liver cancer cells.
Results
C1q enhanced the migration and invasion of HepG2 cells. Many studies have shown C1q is involved 
in cell migration and invasion32. Thus, we examined the involvement of C1q in the migration and invasion of liver 
cancer cells. Migration and invasion assays showed average numbers of migrating and invading HepG2 cells were 
significantly increased by C1q (Fig. 1A–D).
C1q enhanced MAPKs signaling in HepG2 cells. To investigate the mechanisms responsible for the 
C1q-induced promotions of HepG2 cell migration and invasion, we examined levels of the MAPKs proteins p38, 
ERK, and JNK in cells treated with or without C1q. These proteins were selected because they are crucial for the 
induction of tumor cell epithelial-mesenchymal transition (EMT)33 As shown in Fig. 2A–D, levels of p38 MAPKs 
were significantly increased in HepG2 treated with C1q for 1 h, and levels of ERK1/2 and JNK were slightly 
Figure 1. C1q enhanced the migration and invasion of HepG2 cells. A migration assay and a matrigel invasion 
assay were used to evaluate the impact of C1q on HepG2 cells migration and invasion. (A) Migration assays 
showed C1q increased the ability of HepG2 cells to migrate. The images were taken 0 and 18 h after monolayers 
were scratched. (C) Matrigel invasion assays showed that C1q enhanced HepG2 cell invasiveness. (B) Migrated 
distances and (D) numbers of invading cells were determined in at least 6 randomly selected microscope fields 
at 10 × and are shown in the bar diagram. *P < 0.05.
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increased at 1 h and returned to baseline at 4 h. To determine whether C1q causes cell migration through MAPK 
signaling, cells were pretreated with PD98059 (MEK1 activation and MAP kinase cascade inhibitor), SB203580 
(p38 MAPK inhibitor), or SP600125 (JNK inhibitor), respectively, and then treated with C1q. Pharmacological 
blockade of MAPKs attenuated C1q-induced HepG2 migration (Fig. 2E and F), which suggested C1q might 
increase HepG2 migration by enhancing signaling through the MAPK pathway.
C1q increased PI3K/Akt signaling in HepG2 cells. Activation of the PI3K/Akt pathway downstream of 
DDR1 signaling is reportedly involved in the development and progression of cancer34,35. To determine whether 
C1q augments PI3K/Akt signaling, HepG2 cells were treated with or without C1q and then subjected to Western 
blot analysis for PI3K, phosphor-Akt and total Akt. As shown in Fig. 3A–C, levels of PI3K and phosphor-Akt 
were significantly increased by C1q treatment. Consistent with activation of the PI3K/Akt pathway, we observed 
inhibition of C1q-induced migration upon pharmacological blockade of the PI3K/Akt pathway (Fig. 3D and E). 
Taken together, these findings suggest that C1q may enhance migration by augmenting PI3K/Akt signaling.
DDR1 was activated by C1q in HepG2 cells. C1q consists of C-terminal globular head region (gC1q) 
and N-terminal collagen-like repeat region (CLR)10. Here, we investigated the effect of C1q on gC1q receptors, 
such as, C1qBP (gC1qR), and on cC1q receptors, such as, calreticulin (cC1qR), CD93, α2β1 integrin, CD91, 
and LAIR-1, and its effects on DDRs. The up-regulation of DDR1 by C1q treatment was evaluated by real-time 
PCR, flow cytometry, and western blot. As shown in Fig. 4A–C, enhanced DDR1 expression was observed in 
C1q-treated HepG2 cells, but DDR2, CD91, β1 integrin, and LAIR1 were not detected. In addition, though 
C1qBP (gC1qR), calreticulin (cC1qR), and CD93 were expressed, these expressions were unaffected by C1q (see 
Supplementary Fig. S1). Additional experiments were performed using SUN182 cells (another HCC cell-line), 
and similar results were obtained (Supplementary Fig. S2). Levels of DDR1 phosphorylation were assessed by 
immunoprecipitation using DDR1 antibody (sc-532) and subsequent immunoblot analysis using phospho-DDR1 
(Y513) antibody (P00905). As shown in Fig. 4D, the phosphorylation of DDR1 was significantly enhanced after 
1 h of C1q treatment. To our knowledge, this is the first time that C1q has been reported to activate DDR1 directly 
in HepG2 cells.
Knockdown of DDR1 suppressed the C1q-induced migration and invasion of HepG2 cells. DDR1 
signaling regulates the migration and invasion of tumor cells27, and thus, we examined the involvement 
of DDR1 in the C1q-mediated progression of hepatic cancer. In HepG2 cells DDR1 siRNA transfection 
dose-dependently reduced DDR1 expression (Fig. 5A). In the presence of C1q, the migration and invasion of 
Figure 2. C1q enhanced MAPKs signaling in HepG2 cells. After treating HepG2 cells with or without C1q 
for the indicated times, the expressions of the phosphorylated and total forms of p38, ERK1/2, and JNK were 
evaluated by western blotting (A). Bar graphs represent the following ratios; p-p38/p38 (B), p-JNK/JNK (C), 
and p-ERK1/2/ERK1/2 (D). Cells were pretreated with MAPKs inhibitors (20 µM each) for 1 h, then monolayers 
were scratched, and then treated with or without C1q. Photographs were taken after treatment for 0 or 18 h (E). 
The bar graph shows migration distances (F). *P < 0.05, **P < 0.01.
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DDR1 siRNA-transfected cells were inhibited as compared to that observed in control siRNA-transfected cells 
(Fig. 5B–F).
C1q induced the expressions of MMP2 and 9 in HepG2 cells. C1q treatment significantly enhanced 
the expressions of MMP2 and 9 (Fig. 6A and B), which suggested C1q might augment cancer progression by 
up-regulating these MMPs. Furthermore, C1q-induced expressions of MMP2 and 9 were significantly reduced 
by DDR1 knockdown (Fig. 6C and D). These findings suggest that C1q-mediated activation of DDR1 and upreg-
ulations of MMP2 and 9 are required for the metastasis and invasion of HepG2 cells.
C1q regulated epithelial-mesenchymal transition (EMT) via DDR1 in HepG2 cells. EMT is a cel-
lular program that allows immotile epithelial cells to convert to motile mesenchymal cells, and thereby, promotes 
the metastasis and invasion of tumor cells. EMT is also critical for the acquisition of malignant phenotypes by epi-
thelial cancer cells36,37. Thus, we investigated the role of C1q in regulation of mesenchymal markers in cells. Our 
results showed that C1q enhanced the expressions of N-cadherin and vimentin and diminished that of E-cadherin 
in C1q treated HepG2 cells as compared with non-treated controls (Fig. 7A–D). Furthermore, C1q enhanced the 
expression of E-cadherin and diminished those of N-cadherin and vimentin in DDR1 siRNA-transfected HepG2 
cells as compared with control siRNA-transfected cells (Fig. 7E–H), which suggested C1q promotes EMT and 
induced the migration and invasion of these cells.
C1q bound to DDR1 in HepG2 cells. In a recent study, it was reported DDR1 has high affin-
ity for collagen, and that C1q has a collagen-like portion10. Based on these observations, we considered C1q 
binds directly to DDR1. We confirmed direct interactions between C1q and DDR1 using ELISA assay and 
Co-Immunoprecipitation (Co-IP). ELISA confirmed C1q directly and dose-dependently bound to DDR1 in 
HepG2 cells (Fig. 8A). And we used a Co-IP approach to detect the potentially direct binding of C1q and DDR1. 
A binding between C1q and DDR1 was detected in HepG2 cells (Fig. 8B).
Figure 3. C1q activated the PI3K/Akt signal pathway in HepG2 cells. The effects of C1q on the expressions of 
PI3K and Akt in HepG2 cells were determined by western blotting. C1q enhanced the expressions of PI3K and 
of phosphorylated Akt. (A) HepG2 cells were treated with 25 µg/mL C1q for 15 min, 1 h, or 4 h. Bar graphs of 
(B) PI3K/Actin and (C) p-Akt/Akt ratios. (D) Pharmacological inhibition of the PI3K/Akt signal pathway by 
wortmannin (20 µM) pretreatment for 1 h inhibited migration significantly more in the presence of C1q than in 
the absence of C1q. (E) Bar diagram showing migration distances. *P < 0.05, **P < 0.01.
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Discussion
During cancer development, the migration and invasion by cancer cells are associated with poor prognoses26. 
Thus, understanding the molecular pathways that orchestrate the tumorigenesis and metastasis of cancer cells is 
likely to aid the development of treatment strategies.
Hepatocytes are involved in the biosynthesis of plasma complement proteins, including C1q38, and it has been 
suggested hepatic complement proteins are involved in many liver functions, such as, glucose release, acute-phase 
response, inflammation, and immune complex clearance38. C1q is an innate immune molecule with a range of 
diverse ligands and functions39. However, the regulatory effects of C1q on tumor progression and the mecha-
nisms responsible are largely unknown. Here, we report, for the first time, C1q binds directly to DDR1, and that 
this interaction induces the migration and invasion of HepG2 cells, and thus, presumably contributes to disease 
dissemination, which concurs with a previous reported that solid phase-bound C1q promotes fetal trophoblast 
cell migration and invasion40.
The up-regulations of MMP2 and MMP9 (downstream targets of DDR1) are considered to be important for 
the metastasis and invasion of HepG2 cells26. In this study, we found C1q significantly enhanced these expres-
sions, and in-line with these results, it was found in a previous study that the expressional up-regulations of 
MMP2 and 9 modulate EMT and promote tumor cell migration and invasion41. These findings suggest C1q 
upregulates MMP2 and 9, and thus, enhances migration and invasion.
The MAPKs are a family of protein-serine/threonine kinases that are highly conserved in mammals. There 
are three major MAPKs, namely, p38, JNK, and ERK1/242, and all three play critical roles in the development 
and progression of cancer43. Furthermore, it has been reported DDR1 interacts with MAPKs15. Accordingly, we 
examined the regulatory effects of C1q on MAPKs in HepG2 cells. C1q was found to activate MAPK signaling in 
these cells, and pharmacological blockades of individual MAPKs significantly attenuated the migratory pheno-
type. These observations concur with those of a previous study, in which MAPK inhibition abrogated the RANKL 
(receptor activator of nuclear factor kappa-B ligand) induced migration of breast cancer cells44. These findings 
suggest C1q modulates MAPK signaling via DDR1 to regulate the migratory and invasive phenotypes of cancer 
cells.
Activation of the PI3K/Akt pathway plays an important role in cancer tumorigenesis and progression34,45 and 
it has been reported PI3K and Akt are a downstream target of DDR1 activation35. In the present study, we found 
C1q activated PI3K/Akt signaling in HepG2 cells, and that pharmacological inhibition of the PI3K/Akt pathway 
significantly inhibited the ability of cells to migrate. Consistent with these results, it was previously reported inhi-
bition of PI3K/Akt signaling inhibited the migration and invasion of colon cancer cells45.
To identify the molecule targeted by C1q during HCC progression, we treated HepG2 cells with or without 
C1q and evaluated the expressions of DDRs and of the well-known C1q receptors, gC1qR and cC1qR. Our results 
showed C1q significantly upregulated DDR1 expression, but not the expressions of gC1qR, cC1qR or DDR2. 
Figure 4. C1q targeted DDR1 in HepG2 cells. Cells treated with or without C1q were harvested and DDR1 
mRNA level was assessed by real-time PCR (A). Cells were treated with the indicated doses of C1q for 18 h and 
DDR1 expressions were analyzed by flow cytometry (B) and Western blot (C). Levels of phosphor-DDR1 and 
total DDR1 in cells treated with C1q for the indicated times were assessed by immunoprecipitation followed by 
western blotting analysis (D). *P < 0.05, **P < 0.01.
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Figure 5. Knockdown of DDR1 attenuated the C1q-induced migration and invasion of HepG2 cells. Evaluation 
of DDR1 protein levels by western blotting after transfection for 36 h with scrambled (siCtrl) or DDR1-specific 
siRNAs (A). Control or DDR1 siRNA-transfected cells were cultured in 48-well plastic plates and allowed to 
adhere. A linear wound was then created in each well using a pipette and cells were treated with or without C1q 
to initiate migration (B). Transfected cells were cultured in transwell inserts in the presence or absence of C1q 
for 18 h and invading cells were counted as described in Materials and Methods (E). Bar diagrams representing 
migration distances (C), and counts of migrating cells (D) and invading cells (F). *P < 0.05, **P < 0.01 vs 
siCtrl + C1q, #P < 0.05 vs siCtrl.
www.nature.com/scientificreports/
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Furthermore, C1q was found to induce the DDR1 tyrosine phosphorylation. Several lines of evidence suggest that 
DDR1 is overexpressed in cancer cells and this upregulation is associated with aggressiveness26,46.
When DDR1 knocked down HepG2 cells were treated with or without C1q, knockdown was found to signifi-
cantly attenuate C1q-induced migration and invasion, indicating C1q activates DDR1 to regulate cancer progres-
sion, which is in-line with previous reports that DDR1 plays important roles in the progression and metastasis of 
breast and lung cancer cells32.
EMT allows tumor cells to dissociate from tumor sites, and thereby, facilitates migration and invasion47 and it 
has been reported DDR1 signaling promotes EMT48. In the present study, C1q significantly reduced the expres-
sion of E-cadherin, but augmented the expressions of N-cadherin and vimentin (E-cadherin, N-cadherin, and 
vimentin are markers of EMT), which agrees with a previous report that DDR1 is involved in the collagen-induced 
upregulation of N-cadherin, and thus, promotes pancreatic tumor growth, invasion, and metastasis48. in addition, 
we examined the role of DDR1 in the C1q-mediated upregulations of MMP2 and 9. DDR1 gene knockdown 
resulted in significant reductions in the mRNA levels MMP2 and MMP9 in C1q-treated cells versus controls, 
suggesting DDR1 is a key regulator of the C1q-mediated aggressiveness of HepG2 cells.
The results of the present study support the notion that C1q directly activates DDR1 in liver cancer cells and 
enhances migratory and invasive phenotypes. Furthermore, our findings identify DDR1 as a target of C1q, and 
suggest that the interaction between the two promotes tumor aggressiveness.
Methods
Cell culture and reagents. HepG2 cells were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone, Logan, 
UT, USA) containing 10% fetal bovine serum (FBS; Hyclone) and 1% of 100 units/ml of penicillin/streptomy-
cin, and incubated at 37 °C in a humidified 5% CO2 incubator. Human C1q was obtained from Quidel (San 
Diego, CA, USA), Collagen I (endotoxin <1.0 EU/ml) from Advanced BioMatrix, Inc. (San Diego, CA, USA), 
Figure 6. C1q induced the expressions of MMPs in HepG2 cells. The effects of C1q on the expressions of 
MMP2 and MMP9 in HepG2 cells were evaluated by real-time PCR. (A) Real-time PCR for MMP2 in C1q 
treated HepG2 cells. Cells were treated with or without the indicated doses of C1q for 6 h, harvested, total RNA 
was prepared, and reverse transcription reactions were performed using SYBR Select Master Mix Reagent. Real-
time PCR was then used to assess MMP2 expressions. (B) Real-time PCR for MMP9 in C1q treated HepG2 
cells. Cells were transfected with control (siCtrl) or DDR1-specific siRNA for 36 h and then treated with or 
without C1q for 6 h. The mRNA expressions of MMP2 (C) and MMP9 (D) were determined by real-time PCR. 
*P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
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Figure 7. C1q regulated epithelial-mesenchymal transition (EMT) via DDR1 in HepG2 cells. The protein levels 
of the EMT markers E-cadherin, vimentin, and N-cadherin were assessed in cells treated with or without C1q 
by western blotting. (A) Cells were treated with the indicated doses of C1q for 18 h and E-cadherin, vimentin, 
N-cadherin, and actin expressions were analyzed by Western blot. (B) Bar graphs of E-cadherin/Actin, (C) 
N-cadherin/Actin, (D) Vimentin/Actin and ratios. (E) Cells were transfected with control (siCtrl) or siDDR1 
for 36 h, treated with or without C1q for 6 h, and Western blotted for E-cadherin, vimentin, N-cadherin and 
actin. (F) Bar graphs of E-cadherin/Actin, (G) N-cadherin/Actin, (H) Vimentin/Actin and ratios. *P < 0.05, 
**P < 0.01.
Figure 8. C1q bound directly to DDR1 in HepG2 cells. The interaction between C1q with DDR1 was 
investigated by ELISA and co-immunoprecipitation (Co-IP). (A) Binding of C1q with DDR1 by ELISA. Plates 
were coated with equal amounts of DDR1 (BSA was used as negative control) and incubated with diluted 
recombinant C1q. Absorbance was measured at 450 nm. C1q was found to dose-dependently bind to DDR1 
with OD values higher than those of the control (BSA). (B) Co-immunoprecipitation of C1q and DDR1 
examined by Western blotting. HepG2 cells were grown in 10 cm plates, treated with or without C1q for 1 h, 
lysed, and subjected to Co-IP. The lysates were with anti-DDR1 antibody or anti-IgG. The immunoprecipitates 
obtained were western blotted using anti-C1q or anti-DDR1 antibodies. As a protein input control, 5% of cell 
lysates were used. *P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
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serum free Opti-MEM from Invitrogen (Invitrogen, CA, USA), and WelFect-EX PLUS Transfection Reagent from 
Welgene (Welgene, Seoul, South Korea). Trizol reagent and the Superscript III kit were obtained from Invitrogen 
(Invitrogen, CA, USA). Radioimmunoprecipitation (RIPA) buffer, rabbit and mouse secondary antibodies, DDR1 
antibody (sc-532), and anti-β-actin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 
Total and/or phosphorylated-p38, -JNK, -ERK, -PI3K, -Akt, phosphor-tyrosine, and ERK antibodies were pur-
chased from Cell Signaling. C1q antibody (ab71940) was obtained from Abcam (Cambridge, UK), and anti-Phos-
pho-DDR1 (Y513) Antibody (P00905) from Bosterbio (California, USA). Control and DDR1 siRNA were from 
Santa Cruz Biotechnology (Santa Cruz, CA), and primers from Genotech (Daejeon, Korea). All other reagents 
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
siRNA transfection. HepG2 cells were transfected with human DDR1 specific siRNA or control siRNA 
for 36 h using WelFect-EX PLUS Transfection Reagent (Welgene, Seoul, South Korea), according to the man-
ufacturer’s instructions. Briefly, HepG2 cells were cultured in 24-well plates in growth medium for 18 h. Then 
remove the growth medium and wash with serum free medium once. Add 0.3 ml serum free medium and incu-
bate into CO2 incubator until adding DNA complex. Cells were then incubated with transfection complex con-
taining 0.5 μg human DDR1 specific siRNA, 0.5 μg control siRNA, and transfection reagent (2 μg Welfect-Ex and 
1.5 μg Enhancer-Q) in serum free Opti-MEM (Invitrogen, USA). After incubate during 3 h, add complete growth 
medium. Transfection was continued for 36 h. siRNA transduction efficacies were confirmed by Western blotting.
Cell migration assay. Cell migration was measured using a monolayer scratch injury assay. Briefly, HepG2 
cells were cultured in 48-well plates for 18 h. Then a uniform scratch (about 500 µm) was gently performed in 
the monolayers using a sterile pipette tip (200 µl). Cells were then washed gently with phosphate-buffered saline 
(PBS) to remove cellular debris to ensure acellular lines. To initiate migration, cells were treated with or without 
C1q in serum-free medium. Cells were then allowed to migrate for 18 h, and images of migration under static cul-
ture in an incubator containing 5 per cent CO2 at 37 °C without serum were acquired at 0 and 18 h. Wound widths 
were measured using an Olympus IX71 microscope (Olympus Optical Co. Ltd., Tokyo, Japan). Selected repre-
sentative images were obtained, and results were quantified using Image J software (NIH, Bethesda MD, USA).
Cell matrigel invasion assay. Matrigel invasion assays were performed using 6-well transwell plates 
(Becton Dickinson, Bedford, MA), as previously described25. HepG2 cells were cultured in medium with or with-
out C1q, and seeded in top chambers with a Matrigel-coated membrane (6-well insert; pore size, 8 mm). After 
18 hours of culture, invasive cells moved through the matrix and adhered to the bottom membrane of the insert. 
Cells that did not invade through pores were removed, and invading cells were stained with 0.1% crystal violet. 
Cells were photographed as described above for the migration assay, and counted in at least 3 fields (counts were 
then averaged).
Flow cytometry. The expressions of cell surface antigens of DDR1 were evaluated by using FACS Calibur 
(Beckton-Dickinson, San Diego, CA). Cells were cultured in 12-well cell culture plates and incubated in a 5% CO2 
with humidified air at 37 °C. Cells were serum starved for 2 h before complement treatment. C1q was diluted to 
the desired concentration with culture medium and added to each well. Cell culture was continued for 18 h at 
37 °C in 5% CO2 and then 1 × 105 cells were collected, centrifuged at 1200 rpm for 5 min, and re-suspended in 
100 μL of 0.1% sodium azide buffer. Anti- DDR1 (1:1000 dilution) primary antibody (1 μg) was then added and 
cells were incubated at room temperature in the dark for 30 min, washed twice and 1 μg FITC-conjugated sec-
ondary antibody (1:1000 dilution) in 0.1% sodium azide was added. Cells were then incubated for 30 min in the 
dark at room temperature, washed twice, treated with 400 μL 0.1% sodium azide buffer was added, and subjected 
to flow cytometry.
Real-time PCR. Total RNA was extracted using Trizol reagent, according to the manufacturer’s instructions. 
Total RNA (2 µg) was used to synthesize cDNA using a Super Script TM III kit. mRNA expressions were quan-
titatively using the ABI Real-Time PCR system (Applied Biosystems, Inc., Forster City, CA) and SYBR Green 
PCR Master Mix (Life Technologies). GAPDH was used as the internal control. The primer sequences used for 
real-time PCR are shown in Table 1.
Gene Forward Reverse Size
DDR1 GCTGGGGTCAGGAGGTGAT AATACATTGTCTGCC 207
DDR2 GAGGCCAGATTCCAGATGAG GGTGTGCAAGTCAATCTGCA 167
gC1qR ACAACAGCATCCCACCAA GCCTTCTTGCCATCAT 136
cC1qR AAGGTTTGCAGACAAGCCAG CCTTCTTGGTGCCAGG 240
Beta1 AGAATCCAGAGTGTCCCACTG TTCCCTCATACTTCGGATTGA 237
Cd91 TCTGCGATGGCGACAATGAC AATGGAGCAATGGAA 212
Cd93 TCCTGTGCAAGGAGAAGGCC AGGCACAGGTCACC 192
LAIR-1 CAGCATCCAGAAGGTTCGTTA GAACAGGCAGGTGAC 176
GAPDH GTTAGGAAAGCCTGCCGGTG GCATCACCCGGAGGAGAAATC 118
Table 1. Primers used for PCR.
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Immunoprecipitation and Western blot analysis. Cells were lysed in ice-cold RIPA buffer for 40 min 
and centrifuged (12,000 g) for 20 min at 4 °C. Protein concentrations were measured using the bicinchoninic 
acid method. For immunoprecipitation, total cell lysates were incubated with Protein A agarose (Santa Cruz, 
CA) with an rabbit polyclonal DDR1 antibody. Bound proteins were eluted with 2 × SDS-sample buffer and ana-
lyzed by Western blotting. Briefly, 20 μg of lysates were subjected to SDS-polyacrylamide gel electrophoresis and 
transferred to polyvinylidene difluoride (PVDF) membranes (Amersham Pharmacia Biotech). Membranes were 
blocked with 5% bovine serum albumin (BSA) in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 
1 h at room temperature, probed with primary antibodies (as indicated) at 4°C overnight, washed with TBST 
4 times, and incubated with horseradish peroxidase (HRP)-conjugated secondary antibody for 45 min at room 
temperature. Membranes were then rewashed 3 times with TBST and proteins were visualized using an enhanced 
chemiluminescence detection kit (Millipore, MA, USA). Membranes were measured using Fusion Fx gel doc-
umentation system (Vilber Lourmat, Marne-la-Vallee, France). Western band densitometry calculations were 
perforned using Gel Quant NET software.
ELISA. C1q binding was investigated by ELISA. Briefly, 96-well plates were coated with 2 µg of purified full 
length human DDR1 protein (Quidel, San Diego, CA, USA) in 200 μl of carbonate buffer at 4 °C overnight. BSA 
was included as a negative control. Plates were blocked with 10% FBS in PBS and then increasing concentra-
tions of C1q (0, 0.625, 1.25, 2.5, or 5 µg/mL) were added. Protein binding was assessed using anti-C1q (dilution 
1:100) and subsequent incubation with HRP-conjugated anti-rabbit IgG (Sigma) (1:500), both incubations were 
performed at 37 °C for 2 hours. Wells were then washed 3 times, and 100 μl of TMB solution was added imme-
diately to each well, and incubated for 15 minutes at room temperature. After adding 50 μl of 2 N sulfuric acid 
(Stop Solution) to each well, absorbance at 450 nm was measured using a microplate reader Multiskan Spectrum 
(Thermo Scientific).
Statistical analysis. All values are expressed as means ± S.D. Statistical significance was determined using 
the Student’s t-test. Statistical significance was accepted for p values < 0.05.
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